Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Original Article
  • Published:

Cost-effectiveness of irbesartan/hydrochlorothiazide in patients with hypertension: an economic evaluation for Sweden

Journal of Human Hypertension volume 22, pages 845–855 (2008)Cite this article

Abstract

Irbesartan, an angiotensin-II inhibitor, has been shown to be an effective antihypertensive agent in clinical trials. The purpose of this study was to assess the cost-effectiveness of irbesartan in combination with hydrochlorothiazide (HCTZ) in Swedish health-care setting by predicting clinical events and life years based upon observed reductions in blood pressure in clinical trials. The cost-effectiveness of antihypertensive treatment with irbesartan compared with placebo and to other selected angiotensin-II inhibitors (losartan, valsartan, candesartan) in combination with HCTZ was estimated using a Markov model. The incidence of cardiovascular disease was obtained from the Swedish inpatient registry, whereas the risk reductions associated with antihypertensive therapy were taken from the medical literature. Costs for antihypertensive therapy and for treatment of cardiovascular events were included, and the health effects were measured in terms of quality-adjusted life years (QALYs). The study was conducted from a health-care payer perspective. For a 55-year-old male, irbesartan 150 mg/HCTZ 12.5 mg was a dominant strategy (better health effects at lower costs) when compared with losartan 50 mg/HCTZ 12.5 mg and valsartan 80 mg/HCTZ 12.5 mg, and the cost-effectiveness ratio compared with placebo was €3500 per QALY gained. In moderate-to-severe hypertension, irbesartan was cost-effective compared with losartan, whereas the results compared with candesartan were mixed. High-dose combination therapy of irbesartan was also found to be cost-effective compared with low-dose combination therapy. The results from the model indicate that irbesartan provides a cost-effective antihypertensive treatment strategy compared with both placebo, and to valsartan and losartan.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1

Similar content being viewed by others

References

  1. Berkin KE, Ball SG . Essential hypertension: the heart and hypertension. Heart 2001; 86: 467–475.

    Article  CAS  Google Scholar 

  2. MacMahon S, Peto R, Cutler J, Collins R . Blood pressure, stroke, and coronary artery disease. Part 1, prolonged differences in blood pressure: prospective observational studies corrected for the regression dilution bias. Lancet 1990; 335: 765–774.

    Article  CAS  Google Scholar 

  3. Chobanian AV, Bakris GL, Black HR, Cushman WC, Green LA, Izzo JL et al. Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Hypertension 2003; 42: 1206–1252.

    Article  CAS  Google Scholar 

  4. Neal B, MacMahon S, Chapman N . Effects of ACE inhibitors, calcium antagonists, and other blood-pressure-lowering drugs: results of prospectively designed overviews of randomised trials. Blood Pressure Lowering Treatment Trialists' Collaboration. Lancet 2000; 356: 1955–1964.

    Article  CAS  Google Scholar 

  5. Staessen JA, Wang JG, Thijs L . Cardiovascular protection and blood pressure reduction: a meta-analysis. Lancet 2001; 358: 1305–1315.

    Article  CAS  Google Scholar 

  6. Hansson L, Lloyd A, Anderson P, Kopp Z . Excess morbidity and cost of failure to achieve targets for blood pressure control in Europe. Blood Press 2002; 11: 35–45.

    Article  Google Scholar 

  7. Weinehall L, Öhgren B, Persson M, Stegmayr B, Boman K, Hallmans G et al. High remaining risk in poorly treated hypertension: the ‘rule of halves’ still exists. J Hypertens 2002; 20: 2081–2088.

    Article  CAS  Google Scholar 

  8. Croom KF, Curran MP, Goa KL, Perry CM . Irbesartan: A review of its use in hypertension and in the management of diabetic nephropathy. Drugs 2004; 64: 999–1028.

    Article  CAS  Google Scholar 

  9. Asmar R . Targeting effective blood pressure control with angiotensin receptor blockers. Int J Clin Pract 2006; 60: 315–320.

    Article  CAS  Google Scholar 

  10. Sonnenberg FA, Beck JR . Markov models in medical decision making: a practical guide. Med Decis Making 1993; 13: 322–338.

    Article  CAS  Google Scholar 

  11. Lundkvist J, Ekman M, Kartman B, Carlsson J, Jonsson L, Lithell H . The cost-effectiveness of candesartan-based antihypertensive treatment for the prevention of nonfatal stroke: results from the Study on Cognition and Prognosis in the Elderly. J Hum Hypertens 2005; 19: 569–576.

    Article  CAS  Google Scholar 

  12. Glynn RJ, L'Italien GJ, Sesso HD, Jackson EA, Buring JE . Blood pressure lowering and life expectancy based on a Markov model of cardiovascular events. Hypertension 2003; 42: 885–890.

    Article  Google Scholar 

  13. Palmer AJ, Annemans L, Roze S, Lamotte M, Rodby RA, Cordonnier DJ . An economic evaluation of irbesartan in the treatment of patients with type 2 diabetes, hypertension and nephropathy: cost-effectiveness of Irbesartan in Diabetic Nephropathy Trial (IDNT) in the Belgian and French settings. Nephrol Dial Transplant 2003; 18: 2059–2066.

    Article  CAS  Google Scholar 

  14. Rodby RA, Chiou CF, Borenstein J, Smitten A, Sengupta N, Palmer AJ et al. The cost-effectiveness of irbesartan in the treatment of hypertensive patients with type 2 diabetic nephropathy. Clin Ther 2003; 25: 2102–2119.

    Article  CAS  Google Scholar 

  15. Agvall B, Borgquist L, Foldevi M, Dahlstrom U . Cost of heart failure in Swedish primary healthcare. Scand J Prim Health Care 2005; 23: 227–232.

    Article  Google Scholar 

  16. Andersson F, Kartman B . The cost of angina pectoris in Sweden. Pharmacoeconomics 1995; 8: 233–244.

    Article  CAS  Google Scholar 

  17. Ghatnekar O, Persson U, Glader EL, Terent A . Cost of stroke in Sweden: an incidence estimate. Int J Technol Assess Health Care 2004; 20: 375–380.

    Article  Google Scholar 

  18. Zethraeus N, Molin T, Henriksson P, Jonsson B . Costs of coronary heart disease and stroke: the case of Sweden. J Intern Med 1999; 246: 151–159.

    Article  CAS  Google Scholar 

  19. Price list, Södra Regionvårdsnämnden. [Internet] [Accessed: 2 August 2006]. Lund/Malmö, 2006. Available from: http://www.srvn.org/prislista.htm.

  20. Price list, Sydöstra sjukvårdsregionen. [Accessed: 2 August 2006]. Linköping, 2006. Available from: http://www.lio.se/upload/16047/Prislista%202006.pdf.

  21. Price list, Stockholm/Gotland. [Accessed: 2 August 2006]. Stockholm, 2006. Available from: http://extern.bkv.sll.se/samv.sthlm-gotland/.

  22. Price list, Uppsala-Örebroregionen. [Accessed: 2 August 2006]. Uppsala, 2006. Available from: http://www.externt9.lul.se/svn/priser06.htm.

  23. Price list, Norra sjukvårdsregionen. [Internet] [Accessed: 2 August 2006]. Umeå, 2006. Available from: http://www.norrlandstingen.nu/lankar_prislistor.htm.

  24. Price list, Västra sjukvårdsregionen. [Internet] [Accessed: 2 August 2006]. Skövde, 2006. Available from: http://www.vgregion.se/upload/svn%20-%20samverkansnämden/Utomlänspriser%202006%20Västra%20sjukvårdsreg.pdf.

  25. FASS—Pharmaceutical Specialties in Sweden. [Accessed: 24 January 2008]. LIF—Läkemedelsindustriföreningen, Stockholm, 2008. Available from: http://www.fass.se/LIF/home/index.jsp?UserTypeID=0.

  26. Gold MR,, Siegel JE, Russell RB, Weinstein MC . Cost-Effectiveness in Health and Medicine. Oxford University Press: New York, 1996.

    Google Scholar 

  27. Eichler HG, Kong SX, Gerth WC, Mavros P, Jönsson B . Use of cost-effectiveness analysis in health-care resource allocation decision-making: how are cost-effectiveness thresholds expected to emerge? Value Health 2004; 7: 518–528.

    Article  Google Scholar 

  28. Bobrie G, Delonca J, Moulin C, Giacomino A, Postel-Vinay N, Asmar R . A home blood pressure monitoring study comparing the antihypertensive efficacy of two angiotensin II receptor antagonist fixed combinations. Am J Hypertens 2005; 18: 1482–1488.

    Article  CAS  Google Scholar 

  29. Neutel JM, Smith D . Ambulatory blood pressure comparison of the anti-hypertensive efficacy of fixed combinations of irbesartan/hydrochlorothiazide and losartan/hydrochlorothiazide in patients with mild-to-moderate hypertension. J Int Med Res 2005; 33: 620–631.

    Article  CAS  Google Scholar 

  30. Neutel JM, Franklin SS, Oparil S, Bhaumik A, Ptaszynska A, Lapuerta P . Efficacy and safety of irbesartan/HCTZ combination therapy as initial treatment for rapid control of severe hypertension. J Clin Hypertens (Greenwich) 2006; 8: 850–857; quiz 858–859.

    Article  CAS  Google Scholar 

  31. Salerno CM, Demopoulos L, Mukherjee R, Gradman AH . Combination angiotensin receptor blocker/hydrochlorothiazide as initial therapy in the treatment of patients with severe hypertension. J Clin Hypertens (Greenwich) 2004; 6: 614–620.

    Article  CAS  Google Scholar 

  32. Koenig W, on behalf of the Multicentre Study Group. Comparison of the efficacy and tolerability of combination tablets containing candesartan cilexetil and hydrochlorothiazide or losartan and hydrochlorothiazide in patients with moderate to severe hypertension: Results of the CARLOS-study. Clin Drug Invest 2000; 19: 239–246.

    Article  CAS  Google Scholar 

  33. Neutel JM, Saunders E, Bakris GL, Cushman WC, Ferdinand KC, Ofili EO et al. The efficacy and safety of low- and high-dose fixed combinations of irbesartan/hydrochlorothiazide in patients with uncontrolled systolic blood pressure on monotherapy: the INCLUSIVE trial. J Clin Hypertens (Greenwich) 2005; 7: 578–586.

    Article  CAS  Google Scholar 

  34. Glynn RJ, L'Italien GJ, Sesso HD, Jackson EA, Buring JE . Development of predictive models for long-term cardiovascular risk associated with systolic and diastolic blood pressure. Hypertension 2002; 39: 105–110.

    Article  CAS  Google Scholar 

  35. Kaplan EL, Meier P . Nonparametric estimation from incomplete observations. J Am Stat Assoc 1958; 53: 457–481.

    Article  Google Scholar 

  36. Ford ES, Giles WH, Croft JB . Prevalence of nonfatal coronary heart disease among American adults. Am Heart J 2000; 139: 371–377.

    Article  CAS  Google Scholar 

  37. Kannel WB . Incidence and epidemiology of heart failure. Heart Fail Rev 2000; 5: 167–173.

    Article  CAS  Google Scholar 

  38. Kannel WB, Belanger AJ . Epidemiology of heart failure. Am Heart J 1991; 121: 951–957.

    Article  CAS  Google Scholar 

  39. Lloyd-Jones DM, Larson MG, Leip EP, Beiser A, D'Agostino RB, Kannel WB et al. Lifetime risk for developing congestive heart failure: the Framingham Heart Study. Circulation 2002; 106: 3068–3072.

    Article  Google Scholar 

  40. Mejhert M, Persson H, Edner M, Kahan T . Epidemiology of heart failure in Sweden—a national survey. Eur J Heart Fail 2001; 3: 97–103.

    Article  CAS  Google Scholar 

  41. Truelsen T, Piechowski-Jozwiak B, Bonita R, Mathers C, Bogousslavsky J, Boysen G . Stroke incidence and prevalence in Europe: a review of available data. Eur J Neurol 2006; 13: 581–598.

    Article  CAS  Google Scholar 

  42. Conroy RM, Pyorala K, Fitzgerald AP, Sans S, Menotti A, De Backer G et al. Estimation of ten-year risk of fatal cardiovascular disease in Europe: the SCORE project. Eur Heart J 2003; 24: 987–1003.

    Article  CAS  Google Scholar 

  43. Lindholm LH, de Faire U, Persson M, Hedblad B, Ribacke M, Agenäs I . Moderately Elevated Blood Pressure. Swedish Council on Technology Assessment in Health Care: Stockholm, 2004.

    Google Scholar 

  44. Burström K, Johannesson M, Diderichsen F . Swedish population health-related quality of life results using the EQ-5D. Qual Life Res 2001; 10: 621–635.

    Article  Google Scholar 

  45. Tengs TO, Lin TH . A meta-analysis of quality-of-life estimates for stroke. Pharmacoeconomics 2003; 21: 191–200.

    Article  Google Scholar 

  46. Kirsch J, McGuire A . Establishing health state valuations for disease specific states: an example from heart disease. Health Econ 2000; 9: 149–158.

    Article  CAS  Google Scholar 

  47. Kassler-Taub K, Littlejohn T, Elliott W, Ruddy T, Adler E . Comparative efficacy of two angiotensin II receptor antagonists, irbesartan and losartan in mild-to-moderate hypertension. Irbesartan/Losartan Study Investigators. Am J Hypertens 1998; 11: 445–453.

    Article  CAS  Google Scholar 

  48. Oparil S, Guthrie R, Lewin AJ, Marbury T, Reilly K, Triscari J et al. An elective-titration study of the comparative effectiveness of two angiotensin II-receptor blockers, irbesartan and losartan. Irbesartan/Losartan Study Investigators. Clin Ther 1998; 20: 398–409.

    Article  CAS  Google Scholar 

  49. Conlin PR, Spence JD, Williams B, Ribeiro AB, Saito I, Benedict C et al. Angiotensin II antagonists for hypertension: are there differences in efficacy? Am J Hypertens 2000; 13: 418–426.

    Article  CAS  Google Scholar 

  50. Baguet JP, Legallicier B, Auquier P, Robitail S . Updated meta-analytical approach to the efficacy of antihypertensive drugs in reducing blood pressure. Clin Drug Investig 2007; 27: 735–753.

    Article  CAS  Google Scholar 

  51. Baguet JP, Robitail S, Boyer L, Debensason D, Auquier P . A meta-analytical approach to the efficacy of antihypertensive drugs in reducing blood pressure. Am J Cardiovasc Drugs 2005; 5: 131–140.

    Article  CAS  Google Scholar 

  52. Oparil S, Williams D, Chrysant SG, Marbury TC, Neutel J . Comparative efficacy of olmesartan, losartan, valsartan, and irbesartan in the control of essential hypertension. J Clin Hypertens (Greenwich) 2001; 3: 283–291, 318.

    Article  CAS  Google Scholar 

  53. Elmfeldt D, Olofsson B, Meredith P . The relationships between dose and antihypertensive effect of four AT1-receptor blockers. Differences in potency and efficacy. Blood Press 2002; 11: 293–301.

    Article  Google Scholar 

  54. Palmer AJ, Annemans L, Roze S, Lamotte M, Rodby RA, Bilous RW . An economic evaluation of the Irbesartan in Diabetic Nephropathy Trial (IDNT) in a UK setting. J Hum Hypertens 2004; 18: 733–738.

    Article  CAS  Google Scholar 

  55. Palmer AJ, Tucker DM, Valentine WJ, Roze S, Gabriel S, Cordonnier DJ . Cost-effectiveness of irbesartan in diabetic nephropathy: a systematic review of published studies. Nephrol Dial Transplant 2005; 20: 1103–1109.

    Article  CAS  Google Scholar 

Download references

Acknowledgements

This study was funded by Sanofi-Aventis and Bristol-Myers Squibb.

Author information

Authors and Affiliations

  1. i3 Innovus, Stockholm, Sweden

    M Ekman

  2. Department of Health Economics and Reimbursement, Sanofi-Aventis, Paris, France

    C Bienfait-Beuzon

  3. Outcomes Research, Bristol-Myers Squibb, Princeton, NJ, USA

    J Jackson

Authors
  1. M Ekman
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. C Bienfait-Beuzon
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. J Jackson
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to M Ekman.

Additional information

Supplementary Information accompanies the paper on the Journal of Human Hypertension website (http://www.nature.com/jhh)

Supplementary information

Rights and permissions

Reprints and permissions

About this article

Cite this article

Ekman, M., Bienfait-Beuzon, C. & Jackson, J. Cost-effectiveness of irbesartan/hydrochlorothiazide in patients with hypertension: an economic evaluation for Sweden. J Hum Hypertens 22, 845–855 (2008). https://doi.org/10.1038/jhh.2008.76

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/jhh.2008.76

Keywords

This article is cited by

Search

Advanced search

Quick links